EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment

Austin Kulasekararaj iD, Phillip Scheinberg iD, Maria-Magdalena Balp iD, Olivier Somenzi iD, Anggie Wiyani iD, Josefin Snellman iD, Sarah Walsh iD, Katharina Pannagl iD, Jason Steenkamp iD, Régis Peffault de Latour iD

Journal of Comparative Effectiveness Research · 2026-04 · 15 (4)

DOI: 10.57264/cer-2025-0167 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-04. Verfasst von Austin Kulasekararaj und 9 weiteren Autor:innen. Beteiligte Einrichtung: King's College Hospital NHS, London, UK. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Polyethylene Glycols, Anemia, Complement C3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study conducted an indirect treatment comparison (ITC) of iptacopan, the first oral monotherapy targeting factor B, versus pegcetacoplan, a subcutaneous infusion targeting complement component 3, in patients with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia despite complement component 5 inhibitors (C5i). An unanchored matching adjusted ITC was performed, using phase III APPLY-PNH and PEGASUS studies, identified by a systematic literature review. The outcomes were: change from baseline (CfB) in hemoglobin (Hb), with and without post-transfusion data, CfB in lactate dehydrogenase (LDH), CfB in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, transfusion avoidance, and serious adverse events. Two adjustment scenarios were analyzed: (A) baseline Hb, sex, transfusion history ≤12 months, and (B) scenario A plus reticulocyte count, baseline LDH and age. After matching and adjusting, baseline characteristics were similar across trials. Iptacopan showed greater Hb improvements than pegcetacoplan with post-transfusion data (mean difference – scenario A: 1.05 g/dl; p < 0.001, scenario B: 0.76 g/dl; p = 0.018) and without (A: 1.31 g/dl; p < 0.001, B: 1.01 g/dl; p = 0.014). Odds of transfusion avoidance were higher with iptacopan (A: odds ratio [OR] = 9.17, p = 0.013; B: OR = 12.71, p = 0.009). No significant difference was noted in CfB in LDH and FACIT-Fatigue score. These findings suggest that iptacopan may improve Hb levels and reduce transfusion dependency compared with pegcetacoplan in PNH patients with residual anemia despite C5i and must be interpreted in the context of ITCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalPolyethylene GlycolsAnemiaComplement C3HumansFemaleMaleMiddle AgedHemoglobinsAdultTreatment OutcomeAgedBenzoatesIndolesPeptides, CyclicPiperidines

Stichwörter der Autor:innen

comparative effectiveness researchindirect treatment comparisoniptacopanmatching adjusted indirect comparisonparoxysmal nocturnal hemoglobinuriatreatment experienced

Substanzen

Polyethylene GlycolspegcetacoplanHemoglobinsComplement C3iptacopanBenzoatesIndolesPeptides, CyclicPiperidines

Autor:innen und Institutionen

  • King's College Hospital NHS, London, UK.
  • National Institute for Health & Care Research & Wellcome King's Research Facility, London, UK.
  • King's College London, London, UK.
  • Hospital A Beneficência Portuguesa, São Paulo, Brazil.
  • Novartis Pharma AG, Basel, Switzerland.
  • Novartis Pharmaceuticals UK Ltd, London, UK.

ORCID-Profile: Austin Kulasekararaj, Phillip Scheinberg, Maria-Magdalena Balp, Olivier Somenzi, Anggie Wiyani, Josefin Snellman, Sarah Walsh, Katharina Pannagl, Jason Steenkamp, Régis Peffault de Latour

Zitieren

APA

Kulasekararaj, A., Scheinberg, P., Balp, M. M., Somenzi, O., Wiyani, A., Snellman, J., Walsh, S., Pannagl, K., Steenkamp, J., & de Latour, R. P. (2026). Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment. Journal of Comparative Effectiveness Research, 15(4). https://doi.org/10.57264/cer-2025-0167

Vancouver

Kulasekararaj A, Scheinberg P, Balp MM, Somenzi O, Wiyani A, Snellman J, et al. Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment. Journal of Comparative Effectiveness Research. 2026;15(4). doi:10.57264/cer-2025-0167

BibTeX
@article{Kulasekararaj2026,
  author = {Kulasekararaj, Austin and Scheinberg, Phillip and Balp, Maria-Magdalena and Somenzi, Olivier and Wiyani, Anggie and Snellman, Josefin and Walsh, Sarah and Pannagl, Katharina and Steenkamp, Jason and de Latour, Régis Peffault},
  title = {Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.57264/cer-2025-0167}
}
Kostenlos starten →